1. Stem Cell/Wnt TGF-beta/Smad Immunology/Inflammation GPCR/G Protein
  2. TGF-beta/Smad CCR
  3. Pirfenidone

Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities.

For research use only. We do not sell to patients.

Pirfenidone Chemical Structure

Pirfenidone Chemical Structure

CAS No. : 53179-13-8

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
USD 79 In-stock
Solution
10 mM * 1 mL in DMSO USD 79 In-stock
Solid
100 mg USD 72 In-stock
200 mg USD 90 In-stock
500 mg USD 120 In-stock
1 g USD 180 In-stock
5 g USD 264 In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 46 publication(s) in Google Scholar

Other Forms of Pirfenidone:

Top Publications Citing Use of Products

45 Publications Citing Use of MCE Pirfenidone

WB

    Pirfenidone purchased from MedChemExpress. Usage Cited in: Radiat Res. 2018 Oct;190(4):396-403.  [Abstract]

    Western blots are shown of collagen I, collagen III, TGF-b1, p-Smad3 and Smad3 proteins in lung tissue homogenates from different groups.

    View All CCR Isoform Specific Products:

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities[1][2][3].

    IC50 & Target

    TGF-β2[1]

    Cellular Effect
    Cell Line Type Value Description References
    HFL1 IC50
    0.71 μM
    Compound: PIRF; NSC748456
    Antifibrotic activity in HFL1 cells assessed as inhibition of cell viability after 48 hrs by sulforhodamine B assay
    Antifibrotic activity in HFL1 cells assessed as inhibition of cell viability after 48 hrs by sulforhodamine B assay
    [PMID: 26896707]
    HFL1 IC50
    9148 μM
    Compound: PFD
    Antiproliferative activity against human HFL1 cells assessed as reduction in cell proliferation measured after 24 hrs by CCK-8 assay
    Antiproliferative activity against human HFL1 cells assessed as reduction in cell proliferation measured after 24 hrs by CCK-8 assay
    [PMID: 34355186]
    MRC5 IC50
    14.44 mM
    Compound: Pirfenidone
    Antifibrotic activity in human MRC5 cells assessed as inhibition of cell growth after 24 hrs by MTT assay
    Antifibrotic activity in human MRC5 cells assessed as inhibition of cell growth after 24 hrs by MTT assay
    [PMID: 24332090]
    NIH3T3 IC50
    13.72 mM
    Compound: 1; PFD
    Antiproliferative activity against TGFbeta-induced mouse NIH3T3 cells assessed as cell growth inhibition incubated for 48 hrs by CCK-8 assay
    Antiproliferative activity against TGFbeta-induced mouse NIH3T3 cells assessed as cell growth inhibition incubated for 48 hrs by CCK-8 assay
    [PMID: 35694690]
    NIH3T3 IC50
    454 μM
    Compound: 1
    Antiproliferative activity against mouse NIH/3T3 cells after 72 hrs by MTT assay
    Antiproliferative activity against mouse NIH/3T3 cells after 72 hrs by MTT assay
    [PMID: 28122457]
    In Vitro

    Pirfenidone (PFD) reduces the protein levels of the matrix metalloproteinase (MMP)-11, a TGF-β target gene and furin substrate involved in carcinogenesis. These data define PFD or PFD-related agents as promising agents for human cancers associated with enhanced TGF-β activity[1]. In RAW264.7 cells, a murine macrophage-like cell line, Pirfenidone suppresses the proinflammatory cytokine TNF-α by a translational mechanism, which is independent of activation of the MAPK2, p38 MAPK, and JNK. In the murine endotoxin shock model, Pirfenidone potently inhibits the production of the proinflammatory cytokines, TNF-α, interferon-γ, and interleukin-6, but enhances the production of the anti-inflammatory cytokine, interleukin-10[2]. Pirfenidone (PFD) shows its inhibitory effects on the proliferation of HLECs. Cell proliferation is attenuated in the 0.3 mg/mL group after 24 hours compare with the control group (P=0.044). The effect is more apparent in the 0.5 mg/mL group at 24, 48, and 72 hours (P<0.05). The proliferation is almost completely inhibited with 1 mg/mL PFD at all the time-points (P<0.01)[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Administration of Pirfenidone (300 mg/kg/day) for 4 wk. Pirfenidone significantly attenuates the score when administered in Bleomycin (BLM)-treated mice (P<0.0001). Moreover, collagen content is quantified in the lungs to evaluate the anti-fibrotic effects of Pirfenidone. The collagen content in the lungs of BLM-treated mice is significantly increased compared with that in saline- or Pirfenidone-treated mice, and this increase is significantly attenuated by Pirfenidone administration on day 28 after BLM treatment (P=0.0012)[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    Molecular Weight

    185.22

    Formula

    C12H11NO

    CAS No.
    Appearance

    Solid

    Color

    White to light yellow

    SMILES

    O=C1C=CC(C)=CN1C2=CC=CC=C2

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 100 mg/mL (539.90 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : 12.5 mg/mL (67.49 mM; Need ultrasonic)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 5.3990 mL 26.9949 mL 53.9898 mL
    5 mM 1.0798 mL 5.3990 mL 10.7980 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  5% DMSO    40% PEG300    5% Tween-80    50% Saline

      Solubility: ≥ 2.75 mg/mL (14.85 mM); Clear solution

    • Protocol 2

      Add each solvent one by one:  5% DMSO    95% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.75 mg/mL (14.85 mM); Clear solution

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 9.09 mg/mL (49.08 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

    • Protocol 2

      Add each solvent one by one:  Saline

      Solubility: 6.67 mg/mL (36.01 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.98%

    References
    Cell Assay
    [3]

    HLECs are seeded in 96-well plates (1×104 cells/well) for 24 hours in α-MEM/10% FBS/1%NEAA, and are cultured in stationary tubes in serum-free medium for 24 hours. And then the culture medium is removed and cells are bathed in α-MEM with 10% FBS and 1% NEAA supplemented with 0, 0.01, 0.1, 0.2, 0.3, 0.5, or 1 mg/mL Pirfenidone for 0, 4, 12, 24, 48, or 72 hours. After incubation with 180 µL α-MEM and 20 µL of 5 mg/mL MTT for 4 hours at 37°C, the MTT solution is discarded. The Formosan precipitates are dissolved in 180 µL DMSO by agitating the dishes for 10 minutes at 200 rpm on an orbital shaker. The absorbance at 490 nm in each well is read with a micro plate reader. We further examined the effects of PFD by refining the concentrations at 0.2, 0.25, 0.3, 0.4, 0.5 and 0.6 mg/mL using the MTT assay[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [4]

    Mice[4]
    Nine-week-old female C57BL/6 mice are used. Pirfenidone is administered orally for 14 days after osmotic pump implantation. The volume of administration is determined according to body weight. Animals are allocated into 4 groups (n=6/group): normal control, BLM, Pirfenidone (300 mg/kg/day), and BLM + Pirfenidone. The Pirfenidone dose is selected according to a report published elsewhere. Pirfenidone is also administered in a therapeutic setting beginning at day 10 to assess the effect of the drug on the fibrotic phase of BLM model mice.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 5.3990 mL 26.9949 mL 53.9898 mL 134.9746 mL
    5 mM 1.0798 mL 5.3990 mL 10.7980 mL 26.9949 mL
    10 mM 0.5399 mL 2.6995 mL 5.3990 mL 13.4975 mL
    15 mM 0.3599 mL 1.7997 mL 3.5993 mL 8.9983 mL
    20 mM 0.2699 mL 1.3497 mL 2.6995 mL 6.7487 mL
    25 mM 0.2160 mL 1.0798 mL 2.1596 mL 5.3990 mL
    30 mM 0.1800 mL 0.8998 mL 1.7997 mL 4.4992 mL
    40 mM 0.1350 mL 0.6749 mL 1.3497 mL 3.3744 mL
    50 mM 0.1080 mL 0.5399 mL 1.0798 mL 2.6995 mL
    60 mM 0.0900 mL 0.4499 mL 0.8998 mL 2.2496 mL
    DMSO 80 mM 0.0675 mL 0.3374 mL 0.6749 mL 1.6872 mL
    100 mM 0.0540 mL 0.2699 mL 0.5399 mL 1.3497 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email Address *

    Phone Number *

     

    Organization Name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Pirfenidone
    Cat. No.:
    HY-B0673
    Quantity:
    MCE Japan Authorized Agent: